Erasmus MC is committed to a healthy population and excellence in healthcare, has broad expertise in fundamental, clinical and public health research, is the top referral hospital for a region of about five million inhabitants and the largest Dutch medical school. Erasmus Universitair Medisch Centrum Rotterdam (EMC) is the largest of the eight university medical centres in The Netherlands.

The project team is composed of experts in the field of medical informatics, MDD, NFs and TB. The Department of Medical Informatics is an interdisciplinary research group within EMC that studies new methods for acquiring, representing, processing, and managing data and knowledge in health care and the biomedical sciences and has developed land marking infrastructure and software for distributed analysis of electronic health records. The Department has a leading role in many FP7 and IMI projects, including the EMIF and EHDN projects that develop a European infrastructure to facilitate the re-use of medical data. The group is heavily involved in the Observational Health Data Sciences and Informatics (OHDSI) Initiative and is leading the European OHDSI Chapter.

The NF expertise centre comprises paediatricians, (paediatric)neurologist, clinical and molecular geneticists, psychiatrists, internist and ophthalmologist, and has collaboration with relevant subspecialists. It coordinates the national NF1 shared care network in the Netherlands, consisting of 11 treatment centres and 2 specialised intervention centers. The expertise center collaborates in the ENCORE group with the department of neuroscience (director prof Y. Elgersma) in translational research on cognitive/behaviour complications of NF1. The genetic department serves for national diagnostic tests for NF1.

The department of MMID has a long-lasting experience in antimicrobial resistance and therapeutics in many aspects from bench to bedside and as such is multidisciplinary. Regarding TB this team is involved in research at 3 different levels: fundamental- by in vitro studies into antibiotic resistance mechanisms and killing kinetics of tuberculosis drugs; translational- by in vitro clinical implementation strategies including pharmacokinetic and pharmacodynamic (PKPD) in vitro model systems for antibiotic studies; translational- by in vivo studies in well-defined and characterized mouse models of tuberculosis caused by susceptible and resistant strains.

The department of Psychiatry has a long-lasting experience in randomised clinical trials in the area of depression, and in the biomarker identification for treatment outcome in depression.